David Roche of Quantum Strategy discusses the prospects of a renminbi-based international payment and reserve system, ...

Giredestrant lowered the risk of disease recurrence or death by 30%, compared with standard-of-care endocrine therapy, ...

Roche Holding shares rose 2.1% Wednesday after the Swiss drugmaker reported positive results from a new study of an ...

Roche said on Wednesday its experimental oral drug giredestrant reduced the risk of breast cancer recurrence by 30% compared ...

Roche received expanded approval from the Food and Drug Administration for a test to diagnose breast cancer. The pharmaceutical company said Monday that the FDA approved the PATHWAY HER2 (4B5) test ...

SCAMMERS OFTEN TARGET OLDER CONSUMERS. AND ACCORDING TO THE LATEST SCAM REPORT FROM THE FEDERAL TRADE COMMISSION, SCAMMERS ...

Roche has lifted the lid on the data behind its second phase 3 giredestrant win, linking the oral selective estrogen receptor ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's Enhertu in combination with Roche's drug, Perjeta, for the first-line treatment of patients with a type of ...

Don’t offer Devin Roche warm bread with butter and jam. If he’s around, don’t raise a glass and wish the bride and groom well ...

Roche’s data on Wednesday come from the Phase III lidERA Breast Cancer study, which assessed the adjuvant use of giredestrant ...

Roche stock could be interesting for patient investors. Learn more about its outlook, pipeline prospects, and upcoming ...

Roche's giredestrant cut recurrence risk by 30% in the phase 3 lidERA study, showing strong benefits in early ER-positive ...